578
Participants
Start Date
April 30, 2012
Primary Completion Date
May 31, 2014
Study Completion Date
November 30, 2014
MEMP1972A
Subcutaneous repeating dose
MEMP1972A
Subcutaneous repeating dose
MEMP1972A
Subcutaneous repeating dose
placebo
Subcutaneous repeating dose
Brasov
Lima
Auckland
Buenos Aires
Buenos Aires
Sofia
Sofia
Sofia
Sofia
Sofia
Quilmes
San Juan Bautista
Rosario
Aucklund
Balassagyarmat
Leuven
Halen
San Miguel de Tucumán
Plovdiv
Debrecen
Salta
Gembloux
Mendoza
Pleven
Stara Zagora
Rousse
Christchurch
Varna
Mosonmagyaróvar
Berlin
The Bronx
Berlin
Pittsburgh
Philadelphia
Piura
Baltimore
Geesthacht
Fairfax
Winston-Salem
Charleston
Albany
Winter Park
Tampa
Birmingham
Magdeburg
Louisville
Guadalajara
Canton
Bochum
Cincinnati
Centerville
Münster
Dnipro
Dnipropetrovsk
Dnipropetrovsk
Iowa City
Greenfield
Mainz
River Forest
Normal
St Louis
Nuevo León
Odesa
Overland Park
Bellevue
Omaha
Oklahoma City
Tulsa
Ivano-Frankivsk
Waco
San Antonio
San Antonio
Lviv
Freiburg im Breisgau
El Paso
El Paso
Centennial
Denver
Twin Falls
Murray
Landsberg
Torrance
Long Beach
Upland
Costa Mesa
Mission Viejo
Fountain Valley
Bakersfield
Redwood City
Stockton
Rancho Cordova
Medford
Spokane
Moscow
Saint Petersburg
S. Petersburg
Saint Petersburg
Craiova
Smolensk
Deva
Cluj-Napoca
Brasov
New Haven
Edison
Teaneck
Providence
Warwick
Buenos Aires
Vancouver
Mississauga
Ottawa
Toronto
Toronto
Toronto
Coswig
Jena
México
Dunedin
Hamilton
Wellington
Lima
Lima
Lima
Lima
Lima
Lima
Miraflores
Bialystok
Bialystok
Bialystok
Katowice
Kielce
Krakow
Lublin
Poznan
Skierniewice
Tarnów
Warsaw
Wroclaw
Bucharest
Bucharest
Bucharest
Kiev
Kyiv
Kyiv
Lead Sponsor
Genentech, Inc.
INDUSTRY